Form 8-K · Current report
AbbVie 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001104659-26-091269
Summary
As part of financing its acquisition of Apogee Therapeutics, AbbVie entered an underwriting agreement with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC to issue and sell $10 billion of senior notes across nine series, from floating-rate notes due 2028 to 6.100% senior notes due 2066, with net proceeds expected at about $9.93 billion. AbbVie expects the sale to close on August 18, 2026, subject to customary closing conditions.
Key points
- The offering comprises $500 million of floating rate notes due 2028 and eight fixed-rate series, including $1.5 billion of 4.875% senior notes due 2031 and $500 million of 6.100% senior notes due 2066.
- The notes are being offered under AbbVie's Form S-3ASR shelf registration statement dated February 14, 2025, at public prices ranging from 99.441% to 100% of principal.
- Net proceeds will also be used for general corporate purposes, which may include repaying or repurchasing outstanding debt, and will reduce commitments under AbbVie's $10.0 billion 364-day delayed draw term loan facility tied to the Apogee acquisition.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01. Other Events. On August 4, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein (collectively, the “Underwriters”), pursuant to which AbbVie agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “2028 Notes”), $1,250,000,000 aggregate…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.